Nomlabofusp demonstrated sustained increases in frataxin and improvements in key clinical outcomes for Friedreich's ataxia, with a favorable safety profile and strong patient interest. Rolling BLA submission is underway, and a global phase III trial will begin soon, targeting a broad patient population.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.